EveryBaby

EveryBaby is a medical device company developing a breakthrough handheld point-of-care device for early and accurate detection of preterm birth risk. Using electrical impedance spectroscopy (EIS) and AI trained on UK clinical data, it assesses the cervix to predict risk from as early as 14 weeks, up to 6 weeks earlier than ultrasound. The device delivers up to 92% accuracy (AUC ~0.92), significantly higher than conventional frontline tools (AUC 0.59–0.67), with results in seconds. Minimally invasive with no blood and no lab, its intuitive design requires minimal training, enabling adoption across settings from tertiary hospitals to community-based care. EveryBaby holds an exclusive worldwide licence to the technology, protected by 3 patent families across 9 jurisdictions.